Method of Treating Neurological Conditions with Oleandrin
AssigneePhoenix Biotechnology, Inc.
InventorsOtis C. ADDINGTON, Robert A. NEWMAN
Life of this patent
Estimating the term…
Abstract
A method of treating neurological condition in a subject by administration of a cardiac glycoside is provided. Alzheimer's disease, Huntington's disease or stroke are treated by administering a therapeutically effective amount of cardiac glycoside, and optionally triterpene(s), to a subject. The cardiac glycoside can be present in a dosage form.
Claims32
1) A method of treating a neurological condition in a subject comprising:
- administering to a subject in need thereof a neuroprotective composition comprising oleandrin and at least one triterpene together present in an effective amount to treat said neurological condition, wherein the at least one triterpene is selected from the group consisting of oleanolic acid, ursolic acid, and betulinic acid, and the at least one triterpene is present in free acid form, salt form, derivative form, prodrug form or a combination thereof.
10) The method of any one of the above claims, wherein the total molar amount of triterpene exceeds the molar amount of oleandrin.
11) The method of any one of the above claims, wherein the neurological condition is selected from the group consisting of Alzheimer's disease, Huntington's disease, stroke, and Parkinson's disease.
14) A time-delayed method of treating stroke in a subject comprising:
- within an acceptable delay period after a subject has suffered the stroke, administering a neuroprotective composition comprising oleandrin and at least one triterpene together present in an amount sufficient to treat said stroke,
- wherein the at least one triterpene is selected from the group consisting of oleanolic acid, ursolic acid, and betulinic acid, and the at least one triterpene is present in free acid form, salt form, derivative form, prodrug form or a combination thereof.
24) The method of any one of the above claims, wherein the total molar amount of triterpene exceeds the molar amount of oleandrin.
25) The method according to any one of the above claims wherein administration of the neuroprotective composition provides a plasma concentration of oleandrin in the subject in the range of 0.005 to 10 ng/ml.
26) The method according to any one of the above claims wherein the neuroprotective composition comprises 0.1 to 50 mg of oleandrin.
27) The method according to any one of the above claims wherein a subject is administered a dose of 12 to 1200 μg of oleandrin.
28) The method according to any one of the above claims wherein the neuroprotective composition is administered on a recurring basis daily, every other day, every second day, every third day, every fourth day, every fifth day, every sixth day, weekly, every other week, every second week, every third week, monthly, bimonthly, semi-monthly, every other month every second month, quarterly, every other quarter, trimesterly, seasonally, semi-annually, or annually.
29) The method according to any one of the above claims wherein the neuroprotective composition is administered one or more times in a day.
31) The method according to any one of the above claims wherein the neuroprotective composition further comprises one or more other therapeutically effective agents.
Dependencies are inferred from the claim text.